top of page

CRISPR Technology as a Therapeutic for Late-Onset Alzheimer’s Disease

Writer's picture: Questioz EditorQuestioz Editor

Jacob Chang


ABSTRACT

Alzheimer's disease (AD), a neurodegenerative disease, is a result of abnormal buildups of protein, such as amyloid and neurofibrillary tangles, in the brain, creating memory loss. While Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) normally functions to facilitate the removal of amyloid plaques and neurofibrillary tangles, mutations in TREM2 render it dysfunctional. Specific mutations in genes such as TREM2 have shown to be a big risk factor in AD. Gene therapy, a relatively recent discovery, can help to replace defective or missing genes. Recent advancements in gene therapy, a treatment for diseases, offer a promising avenue for treating AD by addressing defective or missing genes, such as those related to TREM2. One of the notable gene therapy systems is Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). Here, we review CRISPR and our understanding of TREM2 in hopes of finding a potential therapeutic for AD.





86 views0 comments

Recent Posts

See All

Comparison of urban layouts

Siddharth Jain ABSTRACT The present study provides a comprehensive analysis and comparison of the transportation networks in three of the...

Comments


Volume 1

Volume 2

Contact Us
Email ID - editor.questioz@gmail.com

Terms and Conditions

Questioz cannot be held responsible for any violation of academic integrity. The intellectual property of all contributing researchers will be respected and protected. Questioz reserves the non-exclusive right to republish submitted material with attribution to the author in any other format, including all print, electronic and online media. However, all individual contributors to Questioz retain the right to submit their work for non-exclusive publication elsewhere.

© 2023 by The Thomas Hill. Proudly created with Wix.com

bottom of page